Valeant Pharmaceuticals International (VRX) : The money flow is calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades, which was negative (8.23 million) in Valeant Pharmaceuticals International (VRX). On Monday, The value of composite uptick trades was $142.23 million, whereas, the value of composite downtick trades was $150.46 million and the ratio between the two was 0.95, indicating selling on strength. Traders involved in block trades booked profits in their holdings as seen in the transactions on downticks valued at $9.26 million. $9.1 million was the block trade value on upticks. The ratio between the two was clearly in favor of the bears at 0.98. The negative money flow of ($0.16 million) shows selling on strength. Valeant Pharmaceuticals International (VRX) gained $0.43 intraday at $24.92 and registrered 1.76% for the week.
Shares of Valeant Pharmaceuticals International, Inc. rose by 18.44% in the last five trading days and 16.32% for the last 4 weeks. Valeant Pharmaceuticals International, Inc. has dropped 1.7% during the last 3-month period . Year-to-Date the stock performance stands at -73.84%.
Valeant Pharmaceuticals International (NYSE:VRX): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $25.63 and $25.63 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $26.91. The buying momentum continued till the end and the stock did not give up its gains. It closed at $26.59, notching a gain of 6.70% for the day. The total traded volume was 28,895,668 . The stock had closed at $24.92 on the previous day.
In a related news, Karabelas Argeris N, director of Valeant Pharmaceuticals International, Inc., executed a transaction worth $98,600 on August 11, 2016. A total of 4,000 shares were purchased at an average price of $24.65. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.